Pharmacokinetics, safety, and tolerability of siponimod (BAF312) in subjects with severe renal impairment: A single-dose, open-label, parallel-group study - Concepedia

Concepedia

Publication | Closed Access

Pharmacokinetics, safety, and tolerability of siponimod (BAF312) in subjects with severe renal impairment: A single-dose, open-label, parallel-group study

13

Citations

0

References

2016

Year

Anne Gardin, Angela Dodman, Sampath Kalluri, Srikanth Neelakantham, Xuemei Tan, Eric Legangneux, Kasra Shakeri‐Nejad

International Journal of Clinical Pharmacology and Therapeutics

Abstract

Changes in the plasma exposure of total and unbound siponimod and metabolites M3 and M5 were not considered to be clinically relevant. Further to severe RI, investigation of PK in subjects with mild and moderate RI was not warranted. .